Avalo Therapeutics, Inc.
AVTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $177,946 | $54,041 | $84,224 | $77,806 |
| - Cash | $26,963 | $42,310 | $125,046 | $134,546 |
| + Debt | $0 | $2,679 | $801 | $568 |
| Enterprise Value | $150,983 | $14,410 | -$40,021 | -$56,172 |
| Revenue | $0 | $0 | $0 | $192 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $105 |
| % Margin | – | – | – | 54.7% |
| EBITDA | -$30,555 | -$19,182 | -$14,534 | -$13,243 |
| % Margin | – | – | – | -6,897.4% |
| Net Income | -$30,625 | -$20,765 | -$13,149 | -$35,339 |
| % Margin | – | – | – | -18,405.7% |
| EPS Diluted | -2.19 | -1.92 | -1.25 | 10.47 |
| % Growth | -14.1% | -53.6% | -111.9% | – |
| Operating Cash Flow | -$16,365 | -$11,390 | -$9,457 | -$15,044 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$16,365 | -$11,390 | -$9,457 | -$15,044 |